[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![AponiaAnalytics Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1816152863069925376.png) aponia_analytics [@AponiaAnalytics](/creator/twitter/AponiaAnalytics) on x 4960 followers
Created: 2025-07-06 12:31:39 UTC

$NWBO
NWBO’s long-standing partnership with Cognate wasn’t just strategic—it was foundational. More than XXXXX personalized DCVax-L doses were manufactured under full GMP, making it one of the largest autologous immunotherapy trials ever run. When Charles River paid $875M to acquire Cognate—over 11x revenue—it effectively validated the manufacturing platform NWBO had quietly built. Add to that: DCVax-L lots remain viable after X years in cryostorage, a rarity in cell therapy. That’s not typical. That’s moat.



XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1941837446896820588/c:line.svg)

**Related Topics**
[$875m](/topic/$875m)
[$nwbo](/topic/$nwbo)

[Post Link](https://x.com/AponiaAnalytics/status/1941837446896820588)